Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

AIMOVIG 70 MG

ERENUMAB : 70 MG · DIN 02479613 · NOVARTIS PHARMACEUTICALS CANADA INC

Health Canada status: MARKETED

What is AIMOVIG?

AIMOVIG 70 MG contains ERENUMAB : 70 MG. It is listed in the Health Canada Drug Product Database under DIN 02479613, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 04-Dec-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is AIMOVIG used for?

Prevention of migraine in adults who have at least 4 migraine days per month.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02479613
Brand nameAIMOVIG
Generic / active ingredientERENUMAB : 70 MG
ManufacturerNOVARTIS PHARMACEUTICALS CANADA INC
Strength70 MG
Dosage formSOLUTION
Route of administrationSUBCUTANEOUS
ScheduleSchedule D
ATC codeN02CD01 ERENUMAB
AHFS class28:32.12
BiosimilarNo
Health Canada statusMARKETED
Status date04-Dec-2018
Original market date2018-12-04 00:00:00

How is it administered?

Recommended dose is 70 mg or 140 mg injected subcutaneously once monthly. Administer in abdomen, thigh, or upper arm. Rotate injection sites. Allow to reach room temperature for 30 mins before use.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at 2°C to 8°C. Protect from direct sunlight. Do not freeze. Do not shake. (Note: Must sit at room temperature for 30 mins before injection).

How is it supplied?

Carton containing one 70 mg/mL or 140 mg/mL pre-filled SureClick autoinjector. (Pre-filled syringes are not available in Canada).

Contraindications

Hypersensitivity to erenumab or to any ingredient in the formulation, or component of the container (including dry natural rubber/latex in the needle shield).

Warnings and precautions

Constipation with serious complications (some requiring hospitalization/surgery). Serious hypersensitivity reactions (rash, angioedema, anaphylaxis). Latex sensitivity (needle cover contains rubber).

What can be used instead?

Other Canadian products sharing ATC code N02CD01 ERENUMAB. 2 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
AIMOVIG140 MGSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCMARKETEDDIN 02487306
AIMOVIG140 MGSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCAPPROVEDDIN 02487292
AIMOVIG70 MGSOLUTIONNOVARTIS PHARMACEUTICALS CANADA INCAPPROVEDDIN 02479605

Who else supplies ERENUMAB worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ERENUMAB appears in 20 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for AIMOVIG

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for AIMOVIG

Health Canada Drug Product Database (DPD), DIN 02479613. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.